Detalhe da pesquisa
1.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178152
2.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867034
3.
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Breast Cancer Res Treat
; 175(2): 511-517, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30746637
4.
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging.
Eur J Nucl Med Mol Imaging
; 46(4): 821-830, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506455
5.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146401
6.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26874901
7.
Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
Radiology
; 272(1): 100-12, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24654970
8.
Discordance between cancer prevalence and training: a need for an increase in oncology education.
Clin Med (Lond)
; 13(1): 50-6, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23472496
9.
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Nat Commun
; 14(1): 4444, 2023 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488191
10.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898233
11.
The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer.
Br Dent J
; 232(2): 95-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35091612
12.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Breast
; 66: 69-76, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36194950
13.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
JAMA Oncol
; 7(9): 1291-1301, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264305
14.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Clin Breast Cancer
; 21(1): 80-91.e7, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33183970
15.
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
Breast Cancer Res Treat
; 122(3): 787-94, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20559708
16.
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
N Engl J Med
; 355(18): 1851-62, 2006 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17079759
17.
Planned and unplanned pregnancies in breast cancer survivors.
Breast
; 46: 75-80, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31100574
18.
Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of 18F-Fluoride Metabolic Flux Than with Measurement of 18F-Fluoride PET/CT SUV?
J Nucl Med
; 60(3): 322-327, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30042160
19.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Nat Commun
; 14(1): 4741, 2023 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550302
20.
Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Clin Cancer Res
; 12(7 Pt 1): 2004-13, 2006 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16609009